Dr. Edmond Bendaly from the Cancer Committee at Marion General Hospital in Indiana shares a patient case that stands out from the rest—and proves the importance of consistently monitoring for side effects.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

There’s much to consider when it comes to determining which therapeutic option is best for your metastatic colorectal cancer patients, which is why Dr. Richard Kim is here to walk us through his thought process using this patient case review.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Performing KRAS testing is an essential step clinicians need to take to determine which therapeutic option is best. In fact, skipping this step can actually be detrimental to patients. Here to talk about the important role of KRAS testing in metastatic colorectal cancer is Dr. Richard Kim, Medical Oncologist at Moffitt Cancer Center.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Join Dr. Richard Kim of Moffitt Cancer Center as he reveals how the sidedness of a mCRC tumor affects not only the prognosis, but also the biologic you use for each individual patient.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

From VEGF and EGFR-targeted therapies to emerging immunotherapies, there are several treatment options available to mCRC patients…but that also means that there’s several factors you need to think about before deciding which option is best for each individual patient. Here to break everything down with Dr. Shira Johnson is Dr. Edmond Bendaly, chairman and liaison of the Cancer Committee at Marion General Hospital in Marion, Indiana.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib, with additional agents under development in ALK positive advanced NSCLC.

This activity will review ALK testing, current and emerging treatment options for ALK positive NSCLC, and recognition and management of adverse events associated with these treatments.

The presence of transforming growth factor-beta (TGF-β) in the tumor microenvironment plays a main role in limiting the clinical efficacy of anti-PD-1/PD-L1 checkpoint inhibitors. Not only does TGF-β suppress the normal anti-tumor action of natural killer cells and T cells, but it is also involved in many processes of cancer progression and metastasis, such as fibroid cap formation, epithelial-to-mesenchymal transition, and angiogenesis.

This panel will discuss the latest findings in the role of TGF-β in tumor formation and progression, as well as treatment advances that target PDL1 and TGF-β pathways simultaneously.

For more episodes in this series, visit ReachMD.com/IO.

Jointly provided by and

Although renal cell carcinoma (RCC) accounts for only 2% to 3% of all adult cancers, for those who present with or progress to advanced RCC, the 5-year survival rate has never been above 10%. Several tyrosine-kinase inhibitors (TKIs), along with many other therapies, now occupy a preferred role in treatment of patients with advanced RCC, but this is a rapidly changing field. The emergence of immunotherapy for patients with RCC is reshaping the landscape of treatment options for both patients with relapse/stage IV surgically unresectable RCC and neoadjuvant therapy. Moreover, advances in the understanding of RCC biomarkers may help to identify which patients may benefit from certain therapies allowing for the possibility of more individualized treatment plans. This interactive activity features an interview with a leading expert in RCC as he discusses the current trends in clinical research in RCC treatment and how these findings are expected to impact not only guideline development but also more individualized patient care. This expert interview was recorded at and discusses some of the latest data featured at the 18th Annual Meeting of ...

Despite the importance of genomic profiling and the advent of targeted therapies, chemotherapeutic strategies remain a cornerstone treatment for patients with advanced non–small cell lung cancer (NSCLC). This includes those patients without actionable mutations in the treatment-naive setting as well as patients with NSCLC that progresses on first-line platinum therapy, and NSCLC with genetic alterations that develops resistance to targeted therapies.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on NSCLC.

In this segment, Dr. Rokitka describes the Adolescent and Young Adult (AYA) cancer population including what makes them unique and why they need special attention. Also discussed will be the more common cancer types seen among AYAs and what action(s) to take if a malignancy is suspected in an AYA patient.

This activity is part of a series of in-depth discussions with oncology thought leaders at the Roswell Park Comprehensive Cancer Center in Buffalo, New York targeting primary care and family physicians.

This series was made possible through the generous support of BlueCross BlueShield of Western New York.